Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
Lucid Diagnostics (LUCD) has signed its first concierge medicine contract with LEAA Health, enabling LEAA's membership-based patients to access EsoGuard® Esophageal DNA Test for esophageal precancer testing on a cash-pay basis. This strategic move aims to generate contractually-guaranteed revenue by tapping into the growing concierge medicine market, which is projected to reach $10.9 billion by 2032.
The partnership aligns with Lucid's strategy to expand EsoGuard revenue streams while pursuing Medicare and commercial coverage. LEAA Health will incorporate EsoGuard testing into its enhanced personalized care services, focusing on early detection and preventive healthcare. The collaboration represents a significant step in making innovative precancer detection tools more accessible to patients seeking premium healthcare services.
Lucid Diagnostics (LUCD) ha firmato il suo primo contratto di medicina concierge con LEAA Health, consentendo ai pazienti membri di LEAA di accedere al test DNA EsoGuard® per la rilevazione di precancerosi esofagei su base di pagamento diretto. Questa mossa strategica mira a generare entrate garantite contrattualmente, sfruttando il crescente mercato della medicina concierge, che si prevede raggiungerà 10,9 miliardi di dollari entro il 2032.
La partnership si allinea con la strategia di Lucid di espandere le fonti di reddito di EsoGuard, mentre persegue la copertura Medicare e commerciale. LEAA Health integrerà il test EsoGuard nei suoi servizi di assistenza personalizzata potenziati, concentrandosi sulla rilevazione precoce e sulla salute preventiva. La collaborazione rappresenta un passo significativo per rendere gli strumenti innovativi per la rilevazione di precancerosi più accessibili ai pazienti che cercano servizi sanitari di alta qualità.
Lucid Diagnostics (LUCD) ha firmado su primer contrato de medicina concierge con LEAA Health, lo que permite a los pacientes miembros de LEAA acceder a la prueba de ADN EsoGuard® para la detección de precáncer esofágico mediante pago en efectivo. Este movimiento estratégico tiene como objetivo generar ingresos garantizados contractualizando al aprovechar el creciente mercado de la medicina concierge, que se proyecta alcanzará 10.9 mil millones de dólares para 2032.
La asociación se alinea con la estrategia de Lucid para expandir las fuentes de ingresos de EsoGuard mientras persigue la cobertura de Medicare y comercial. LEAA Health incorporará la prueba EsoGuard en sus servicios de atención personalizada mejorados, enfocándose en la detección temprana y la atención médica preventiva. La colaboración representa un paso significativo para hacer que las herramientas innovadoras de detección de precáncer sean más accesibles para los pacientes que buscan servicios de salud premium.
Lucid Diagnostics (LUCD)는 LEAA Health와 첫 번째 컨시어지 의료 계약을 체결하여 LEAA의 회원 기반 환자들이 현금 결제 방식으로 식도 전암 검사를 위한 EsoGuard® 식도 DNA 검사를 받을 수 있도록 했습니다. 이 전략적 움직임은 증가하는 컨시어지 의료 시장을 활용하여 계약적으로 보장된 수익을 창출하는 것을 목표로 하며, 이 시장은 2032년까지 109억 달러에 이를 것으로 예상됩니다.
이 파트너십은 EsoGuard 수익원 확대와 Medicare 및 상업적 보험 적용을 추구하는 Lucid의 전략과 일치합니다. LEAA Health는 조기 발견 및 예방 건강 관리에 중점을 두고 EsoGuard 검사를 향상된 개인 맞춤형 치료 서비스에 통합할 것입니다. 이 협력은 프리미엄 의료 서비스를 찾는 환자들에게 혁신적인 전암 탐지 도구를 더 접근 가능하게 만드는 중요한 진전을 나타냅니다.
Lucid Diagnostics (LUCD) a signé son premier contrat de médecine concierge avec LEAA Health, permettant aux patients membres de LEAA d'accéder au test ADN EsoGuard® pour le dépistage des précancers œsophagiens sur une base de paiement direct. Ce mouvement stratégique vise à générer des revenus garantis par contrat en exploitant le marché en pleine expansion de la médecine concierge, qui devrait atteindre 10,9 milliards de dollars d'ici 2032.
Le partenariat s'aligne avec la stratégie de Lucid d'élargir les sources de revenus d'EsoGuard tout en poursuivant la couverture Medicare et commerciale. LEAA Health intégrera le test EsoGuard dans ses services de soins personnalisés améliorés, en mettant l'accent sur la détection précoce et la santé préventive. Cette collaboration représente une étape significative pour rendre les outils innovants de détection des précancers plus accessibles aux patients à la recherche de services de santé de qualité supérieure.
Lucid Diagnostics (LUCD) hat seinen ersten Vertrag für Concierge-Medizin mit LEAA Health unterzeichnet, der es den Mitglieder-patienten von LEAA ermöglicht, den EsoGuard® Esophageal DNA Test zur Untersuchung auf Speiseröhrenvorstufen auf Barzahlung zu erhalten. Dieser strategische Schritt zielt darauf ab, vertraglich garantierte Einnahmen zu generieren, indem der wachsende Markt für Concierge-Medizin erschlossen wird, der voraussichtlich bis 2032 10,9 Milliarden Dollar erreichen wird.
Die Partnerschaft stimmt mit Lucids Strategie überein, die Einnahmequellen von EsoGuard zu erweitern, während Medicare und kommerzielle Deckung angestrebt wird. LEAA Health wird den EsoGuard-Test in seine verbesserten personalisierten Dienstleistungen integrieren, wobei der Schwerpunkt auf frühzeitiger Erkennung und präventiver Gesundheitsversorgung liegt. Die Zusammenarbeit stellt einen bedeutenden Schritt dar, um innovative Werkzeuge zur Früherkennung von Vorstufen für Patienten, die nach hochwertigen Gesundheitsdienstleistungen suchen, zugänglicher zu machen.
- Secured first concierge medicine contract, opening new revenue stream
- Establishes presence in growing concierge medicine market ($10.9B by 2032)
- Creates contractually-guaranteed revenue through cash-pay model
- Medicare and commercial coverage still pending
- Revenue impact and contract terms not disclosed
Insights
This strategic partnership marks a significant pivot in Lucid Diagnostics' commercialization strategy, introducing a dual-track approach that combines traditional insurance reimbursement pursuit with direct cash-pay access through concierge medicine. The timing is particularly strategic, as the concierge medicine market's projected growth to
The cash-pay model through concierge practices offers several distinct advantages:
- Accelerated market penetration without waiting for lengthy insurance approval processes
- Higher margins compared to traditional reimbursement models due to elimination of insurance-related overhead
- More predictable revenue streams through contractual guarantees
- Direct access to a patient population more likely to pursue preventive care
The concierge medicine channel could serve as a proving ground for EsoGuard's clinical utility and market acceptance. Success in this premium segment could strengthen Lucid's position in negotiations with insurance providers and Medicare, potentially accelerating broader coverage decisions. The contract with LEAA Health, while being their first in this space, establishes a replicable model for expansion to other concierge networks.
However, this strategy also presents certain considerations: the concierge market, while growing, represents a relatively small portion of the total addressable market for esophageal precancer testing. The success of this initiative will largely depend on Lucid's ability to scale these partnerships across multiple concierge networks while maintaining favorable pricing and terms.
LEAA Health membership-based concierge patients will now have access to EsoGuard esophageal precancer testing as part of their enhanced personalized care service on a cash-pay basis
"We are thrilled to enter into our first concierge medicine contract with LEAA Health to expand access to EsoGuard precancer testing," said Shaun O'Neil, Lucid's President and Chief Operating Officer. "We have committed to growing contractually-guaranteed EsoGuard revenue in parallel with our intensive efforts to secure Medicare and commercial coverage. Our recently launched cash-pay program targeting concierge medicine is an important component of this strategic initiative. Concierge medicine patients actively seek innovative preventive care solutions such as EsoGuard and we are pleased to offer our solution as part of LEAA Health's enhanced personalized care offerings."
"This partnership with Lucid aligns perfectly with LEAA Health's mission to provide top-tier, personalized healthcare solutions to our patients," said Isaak N. Yakubov, Founder and CEO of LEAA Health. "EsoGuard represents a groundbreaking approach to esophageal precancer detection, allowing us to identify potential issues at an early stage when intervention can be most effective. By offering EsoGuard as a screening tool to all eligible patients, we are expanding access to this innovative test and enhancing our ability to deliver proactive, personalized care that could potentially save lives."
The 2024 Annual Report from Concierge Medicine Today indicates that the concierge medicine market in
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-executes-first-concierge-medicine-contract-with-leaa-health-302381394.html
SOURCE Lucid Diagnostics
FAQ
What is the value of Lucid Diagnostics' (LUCD) contract with LEAA Health?
How will LUCD's EsoGuard test be offered through LEAA Health's concierge service?
What is the projected size of the concierge medicine market that LUCD is targeting?
Does LUCD's EsoGuard test currently have Medicare coverage?
What type of testing does LUCD's EsoGuard provide to patients?
